Promega Corporation

AMPK (A2/B1/G1) Kinase Enzyme System

See All Kinase Enzyme Systems
Recombinant full-length human AMPK (combination of A2/B1/G1 subunits) was expressed by baculovirus in Sf9 insect cells using a C-terminal His tag. AMPK (A2/B1/G1) plays a key role in insulin signaling pathway and is a major therapeutic target for the treatment of diabetes (1). AMPK is viewed as a fuel sensor for glucose and lipid metabolism by modulating the activity of the autonomous nervous system in vivo. Short-term overexpression of a constitutively active form of AMPK in the liver leads to mild hypoglycemia and fatty liver due to increased fatty acid utilization (2).

ADP-Glo™...

Expand to Read More »

  • Share
  • Print
  • Email
  • Prices valid for Australian customers only
Product Size Conc. Catalog # *List Price Order QTY Add to Cart
AMPK (A2/B1/G1) Kinase Enzyme System
Close Window

AMPK (A2/B1/G1) Kinase Enzyme System  Components

10μg
- V4014 A$ 1,186.00 Add to cart

AMPK (A2/B1/G1) Kinase Enzyme System

Close Window

AMPK (A2/B1/G1) Kinase Enzyme System

 Components

1mg
- V6275 Please Enquire
ADP-Glo™ Kinase Assay + AMPK (A2/B1/G1) Kinase Enzyme System
Close Window

ADP-Glo™ Kinase Assay + AMPK (A2/B1/G1) Kinase Enzyme System  Components

  • AMPK (A2/B1/G1) Kinase Enzyme System

    V40141 x 10μg
  • ADP-Glo™ Kinase Assay

    V91011 x 1,000 assays
1 each
- V4015 A$ 1,584.00 Add to cart


You Also May Be Interested In

Storage Conditions

Upon receipt, centrifuge the kinase and dispense it into smaller quantities. Store the kinase at –70°C and the rest of the components at –20°C.

For product intended use please see Patents & Disclaimers tab.

Use Restrictions

V4014, V6275, V4015 For Research Use Only. Not for Use in Diagnostic Procedures.

Patents - Disclaimers

V4015 U.S. Pat. Nos. 7,083,911, 7,452,663 and 7,732,128 and other patents.

V4015 U.S. Pat. No. 7,700,310 and other patents and patents pending.

V4015 U.S. Pat. No. 7,741,067 and other patents and patents pending.

V4015 U.S. Pat. Nos. 6,602,677, 7,241,584 and 8,030,017 and other patents and patents pending.

V4015 U.S. Pat. No. 8,183,007 and other patents pending.

V4015 Licensed from Lonza Nottingham Ltd. under U.S. Pat. Nos. 6,599,711 and 6,911,319 and other pending and issued patents.

V4015 The method of recombinant expression of Coleoptera luciferase is covered by U.S. Pat. Nos. 5,583,024, 5,674,713 and 5,700,673.

It appears that you have Javascript disabled. Our website requires Javascript to function correctly. For the best browsing experience, please enable Javascript.